肿瘤化学治疗所致HBV再激活的研究进展  

Research progress on the reactivation of hepatitis B virus due to chemotherapy of tumors

作　　者：关瀛 李莉 Guan Ying;Li Li(Zunyi Medical University,Zunyi 563003,China)

机构地区：[1]遵义医科大学,遵义563003 [2]贵州省黔西南州人民医院,兴安562400

出　　处：《新医学》2020年第3期176-179,共4页Journal of New Medicine

基　　金：贵州省科技计划项目(黔科合SY字[2013]3029号)。

摘　　要：免疫抑制状态下的HBV感染者在接受化学治疗、免疫抑制治疗或生物治疗时,由于这些治疗影响患者自身免疫系统,从而导致抗病毒的免疫功能受损,使原本处于低活跃状态的HBV出现复制增加,引致肝细胞受损,这称之为HBV的再激活。HBV的再激活揭示了HBV的基本特征及其以潜伏感染的形式长期存在的能力。该文主要对肿瘤化学治疗所致HBV再激活的发病率、定义、机制、可能的危险因素、预防和治疗的研究进展进行综述,旨在加深临床医师对HBV再激活现象的认识,提高HBV再激活的防治水平。During chemotherapy,immunosuppressive therapy or biological therapy for hepatitis B virus(HBV)-infected patients in immunosuppressive state,these therapies can affect the autoimmune system and destroy the antiviral immune function,increasing the replication of HBV originally in a low active state and leading to liver cell injury,which is defined as the reactivation of HBV.The reactivation of HBV reveals the fundamental characteristics of HBV and its long-term ability to exist in the form of latent infection.This article mainly reviews the research progress on the incidence,definition,mechanism,potential risk factors,prevention and treatment of HBV reactivation caused by tumor chemotherapy,aiming to deepen the clinicians’understanding of HBV reactivation phenomenon and improve the prevention and treatment level of HBV reactivation.

关 键 词：乙型肝炎病毒 再激活 肿瘤 化学治疗 

分 类 号：R512.62[医药卫生—内科学] R730.53[医药卫生—临床医学]